UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

The American journal of gastroenterology, 2021-10, Vol.116 (10), p.2014-2025

2021

Volltextzugriff (PDF)

Mucosal healing in inflammatory bowel disease

Journal of clinical gastroenterology, 2013-03, Vol.47 (3), p.212-221

Osterman, Mark T

2013

Volltextzugriff (PDF)

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort

Inflammatory bowel diseases, 2020-01, Vol.26 (1), p.103-111

2020

Volltextzugriff (PDF)

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

Clinical gastroenterology and hepatology, 2014-05, Vol.12 (5), p.811-817.e3

2014

Volltextzugriff (PDF)

Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)

Inflammatory bowel diseases, 2021-02, Vol.27 (2), p.207-214

2021

Volltextzugriff (PDF)

Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis

Gastroenterology (New York, N.Y. 1943), 2006-04, Vol.130 (4), p.1047-1053

2006

Volltextzugriff (PDF)

Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

Gastroenterology (New York, N.Y. 1943), 2018-03, Vol.154 (4), p.1201-1202

2018

Volltextzugriff (PDF)

Secular trends in small-bowel obstruction and adhesiolysis in the United States: 1988–2007

The American journal of surgery, 2012-09, Vol.204 (3), p.315-320

2012

Volltextzugriff (PDF)

Infliximab vs. Adalimumab for UC: Is There A Difference?

Clinical gastroenterology and hepatology, 2017-08, Vol.15 (8), p.1197-1199

2017

Volltextzugriff (PDF)

Natalizumab for Crohn’s Disease: Down but Not Out

Clinical gastroenterology and hepatology, 2015-11, Vol.13 (11), p.1926-1928

2015

Volltextzugriff (PDF)

Clozapine-induced acute gastrointestinal necrosis: a case report

Journal of medical case reports, 2017-09, Vol.11 (1), p.270-270, Article 270

2017

Volltextzugriff (PDF)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease

Journal of clinical medicine, 2020-09, Vol.9 (10), p.3142

2020

Volltextzugriff (PDF)

Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Clinical gastroenterology and hepatology, 2017-10, Vol.15 (10), p.1580-1588.e3

2017

Volltextzugriff (PDF)

Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease

Inflammatory bowel diseases, 2018-09, Vol.24 (10), p.2266-2271

2018

Volltextzugriff (PDF)

Can Colonoscopy Reduce the Risk of Colon Cancer and Mortality in Patients With Inflammatory Bowel Disease?

Clinical gastroenterology and hepatology, 2015-09, Vol.13 (9), p.1702-1703

2015

Volltextzugriff (PDF)

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2018-06, Vol.12 (7), p.804-810

2018

Volltextzugriff (PDF)

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis

The American journal of gastroenterology, 2021-05, Vol.116 (5), p.1007-1014

2021

Volltextzugriff (PDF)

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease

The American journal of gastroenterology, 2018-03, Vol.113 (3), p.405-417

2018

Volltextzugriff (PDF)

How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD

Inflammatory bowel diseases, 2016-05, Vol.22 (5), p.1262-1274

2016

Volltextzugriff (PDF)

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

Clinical gastroenterology and hepatology, 2024-05, Vol.22 (5), p.1077-1086.e13

2024

Volltextzugriff (PDF)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Alimentary pharmacology & therapeutics, 2019-02, Vol.49 (4), p.408-418

2019

Volltextzugriff (PDF)

Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age

Clinical gastroenterology and hepatology, 2020-09, Vol.18 (10), p.2262-2268

2020

Volltextzugriff (PDF)

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2011, Vol.9 (1), p.36-41.e1

2011

Volltextzugriff (PDF)

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

JAMA dermatology (Chicago, Ill.), 2016-02, Vol.152 (2), p.164

2016

Volltextzugriff (PDF)

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2014-04, Vol.146 (4), p.941-949.e2

2014

Volltextzugriff (PDF)

1 – 25 von 300

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(267)
Mit Volltextzugriff
(218)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Mucosal healing in inflammatory bowel disease

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)

Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis

Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

Secular trends in small-bowel obstruction and adhesiolysis in the United States: 1988–2007

Infliximab vs. Adalimumab for UC: Is There A Difference?

Natalizumab for Crohn’s Disease: Down but Not Out

Clozapine-induced acute gastrointestinal necrosis: a case report

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease

Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease

Can Colonoscopy Reduce the Risk of Colon Cancer and Mortality in Patients With Inflammatory Bowel Disease?

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease

How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Suchergebnisse filtern